WENTWORTH KORY JAMES
SEC CIK 1725663 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| TRDA | Entrada Therapeutics, Inc. | CFO | 117.3K | — | $1.91M | 51 | 2022-03-01 | 2026-09-02 |
Most active insiders at TRDA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | PARMAR KUSH | Dir, 10% | — | $3.65M |
| 2 | MPM BIOVENTURES 2018, L.P. | 10% | — | $3.60M |
| 3 | MPM BioVentures 2014, L.P. | 10% | — | $3.60M |
| 4 | 5AM Ventures V, L.P. | 10% | — | $3.00M |
| 5 | Baker Bros. Advisors (GP) LLC | 10% | $1.35M | — |
| 6 | WENTWORTH KORY JAMES | CFO | — | $433.6K |
| 7 | Dowden Nathan J | Pres, COO | — | $425.7K |
| 8 | Sethuraman Natarajan | Pres, Research, Develop | — | $398.8K |
| 9 | BAKER FELIX | 10% | $261.8K | — |
| 10 | Zeiher Bernhardt G | Dir | $29.3K | — |
Transactions 51
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-03 17:15 | 2026-09-02 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | F - Tax | $7.14 | -1,733 | 117.3K | -1% | -$12.4K | |
| T | 2026-04-02 16:39 | 2026-04-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale | $12.95 | -2,500 | 119.0K | -2% | -$32.4K |
| M | 2026-03-11 | 2026-03-09+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale | $13.01 | -16.5K | 121.5K | -12% | -$214.4K |
| 2026-03-06 | 2026-03-04 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale | $12.25 | -7,988 | 138.0K | -5% | -$97.9K | |
| DM | 2026-03-03 | 2026-03-02+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | F - Tax | $11.73 | -8,651 | 146.0K | -6% | -$101.4K |
| D | 2026-03-03 | 2026-03-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +44.6K | 154.6K | +41% | $0 |
| 2025-11-24 | 2025-11-21 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale | $9.98 | -8,910 | 110.0K | -7% | -$88.9K | |
| 2025-09-04 | 2025-09-02 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | F - Tax | $5.43 | -1,734 | 118.9K | -1% | -$9,416 | |
| D | 2025-04-04 | 2025-04-03 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +11.1K | 120.7K | +10% | +$23.4K |
| 2025-03-19 | 2025-03-17 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale | $10.67 | -1,784 | 109.5K | -2% | -$19.0K | |
| D | 2025-03-04 | 2025-03-03 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | F - Tax | $11.68 | -4,929 | 111.3K | -4% | -$57.6K |
| D | 2025-03-04 | 2025-03-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +42.4K | 116.2K | +57% | $0 |
| DM | 2024-12-03 | 2024-11-29+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $20.00 | -6,000 | 73.8K | -8% | -$120.0K |
| DM | 2024-12-03 | 2024-11-29+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +6,000 | 74.8K | +9% | +$12.6K |
| D | 2024-11-13 | 2024-11-11 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +6,000 | 82.5K | +8% | +$12.6K |
| D | 2024-11-13 | 2024-11-11 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $19.98 | -8,637 | 73.8K | -10% | -$172.6K |
| 2024-09-10 | 2024-09-09 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale | $14.97 | -3,195 | 76.5K | -4% | -$47.8K | |
| M | 2024-09-05 | 2024-09-03+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | F - Tax | $15.63 | -1,731 | 80.8K | -2% | -$27.1K |
| 2024-07-10 | 2024-07-08 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale | $14.95 | -1,758 | 81.4K | -2% | -$26.3K | |
| D | 2024-03-19 | 2024-03-15 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +9,000 | 83.2K | +12% | +$18.9K |
| 2024-03-08 | 2024-03-06 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale | $12.31 | -4,086 | 74.2K | -5% | -$50.3K | |
| DM | 2024-03-05 | 2024-03-04+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | F - Tax | $12.50 | -2,215 | 80.1K | -3% | -$27.7K |
| D | 2024-03-05 | 2024-03-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +30.9K | 80.5K | +62% | $0 |
| DM | 2023-12-26 | 2023-12-21+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +12.5K | 59.8K | +26% | +$26.2K |
| DM | 2023-12-26 | 2023-12-21+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $15.59 | -12.5K | 49.6K | -20% | -$194.8K |
| D | 2023-09-06 | 2023-09-05 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | F - Tax | $14.46 | -426 | 50.5K | -0.8% | -$6,160 |
| D | 2023-09-06 | 2023-09-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +14.2K | 50.9K | +39% | $0 |
| DM | 2023-09-06 | 2023-09-06 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale | $13.48 | -950 | 49.6K | -2% | -$12.8K |
| DM | 2023-07-12 | 2023-07-10+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +10.0K | 42.9K | +30% | +$21.0K |
| DM | 2023-07-12 | 2023-07-10+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $17.99 | -10.0K | 36.7K | -21% | -$179.9K |
| D | 2023-06-30 | 2023-06-29 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +8,790 | 36.7K | +31% | +$18.5K |
| DM | 2023-06-23 | 2023-06-21 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $15.01 | -17.5K | 28.0K | -38% | -$262.6K |
| D | 2023-06-23 | 2023-06-21 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +17.5K | 45.5K | +63% | +$36.8K |
| DA | 2023-04-19 | 2023-03-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +14.2K | 28.0K | +103% | $0 |
| DM | 2023-03-03 | 2023-03-02 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale | $10.52 | -1,747 | 42.3K | -4% | -$18.4K |
| D | 2023-03-03 | 2023-03-02 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | F - Tax | $11.60 | -1,005 | 43.9K | -2% | -$11.7K |
| D | 2023-03-03 | 2023-03-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +28.4K | 44.9K | +172% | $0 |
| D | 2022-12-12 | 2022-12-08 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +4,550 | 21.1K | +28% | +$9,555 |
| D | 2022-12-12 | 2022-12-08 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $18.95 | -4,550 | 16.5K | -22% | -$86.2K |
| DM | 2022-12-06 | 2022-12-02+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $18.19 | -3,110 | 16.5K | -16% | -$56.6K |
| DM | 2022-12-06 | 2022-12-02+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +3,110 | 19.4K | +19% | +$6,531 |
| D | 2022-11-18 | 2022-11-16 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +200 | 16.7K | +1% | +$420 |
| D | 2022-11-18 | 2022-11-16 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $18.10 | -200 | 16.5K | -1% | -$3,620 |
| 2022-09-06 | 2022-09-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +5,503 | 16.5K | +50% | $0 | |
| D | 2022-08-26 | 2022-08-24 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +1,117 | 15.7K | +8% | +$2,346 |
| DM | 2022-08-26 | 2022-08-24+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $13.79 | -4,669 | 12.8K | -27% | -$64.4K |
| DM | 2022-08-23 | 2022-08-19+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +5,972 | 24.7K | +32% | +$12.5K |
| DM | 2022-08-23 | 2022-08-19+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $13.08 | -11.7K | 16.1K | -42% | -$152.5K |
| DM | 2022-08-18 | 2022-08-16+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | M - OptEx | $2.10 | +300 | 20.6K | +1% | +$630 |
| DM | 2022-08-18 | 2022-08-16+ | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | S - Sale+OE | $13.02 | -600 | 20.2K | -3% | -$7,814 |
| D | 2022-03-03 | 2022-03-01 | TRDA | Entrada Therapeutics, Inc. | WENTWORTH KORY JAMES | CFO | A - Grant | $0.00 | +11.0K | 20.5K | +115% | $0 |
Purchase Sale Sale after option exercise All abbreviations